Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) has been assigned an average rating of “Hold” from the sixteen research firms that are presently covering the firm. Three equities research analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $45.85.
Several brokerages have commented on IONS. Leerink Swann reiterated a “market perform” rating and issued a $40.00 price target on shares of Ionis Pharmaceuticals in a research note on Thursday, November 10th. Needham & Company LLC reiterated a “buy” rating and issued a $64.00 price target on shares of Ionis Pharmaceuticals in a research note on Sunday, January 8th. BMO Capital Markets reiterated an “outperform” rating and issued a $63.00 price target (down previously from $68.00) on shares of Ionis Pharmaceuticals in a research note on Tuesday, January 17th. Janney Montgomery Scott reiterated a “neutral” rating and issued a $54.00 price target (up previously from $50.00) on shares of Ionis Pharmaceuticals in a research note on Wednesday, December 28th. Finally, J P Morgan Chase & Co reiterated a “hold” rating and issued a $35.00 price target on shares of Ionis Pharmaceuticals in a research note on Thursday, November 10th.
In other Ionis Pharmaceuticals news, Chairman Stanley T. Crooke sold 13,200 shares of the company’s stock in a transaction dated Tuesday, January 10th. The shares were sold at an average price of $49.25, for a total value of $650,100.00. Following the transaction, the chairman now directly owns 37,029 shares in the company, valued at approximately $1,823,678.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO B Lynne Parshall sold 12,500 shares of the company’s stock in a transaction dated Thursday, December 1st. The stock was sold at an average price of $42.23, for a total transaction of $527,875.00. Following the completion of the transaction, the chief operating officer now owns 23,693 shares in the company, valued at $1,000,555.39. The disclosure for this sale can be found here. Insiders sold a total of 81,953 shares of company stock worth $3,845,673 over the last 90 days. Insiders own 1.86% of the company’s stock.
A number of institutional investors have recently modified their holdings of the company. Massey Quick & Co. LLC bought a new position in shares of Ionis Pharmaceuticals during the fourth quarter worth approximately $143,000. First Allied Advisory Services Inc. bought a new position in shares of Ionis Pharmaceuticals during the fourth quarter worth approximately $239,000. HL Financial Services LLC bought a new position in shares of Ionis Pharmaceuticals during the third quarter worth approximately $216,000. Gideon Capital Advisors Inc. bought a new position in shares of Ionis Pharmaceuticals during the fourth quarter worth approximately $287,000. Finally, Fred Alger Management Inc. bought a new position in shares of Ionis Pharmaceuticals during the fourth quarter worth approximately $287,000. Institutional investors and hedge funds own 87.76% of the company’s stock.
This piece of content was originally reported by sleekmoney and is the sole property of of sleekmoney. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US & international trademark & copyright law. The legal version of this piece of content can be read at http://sleekmoney.com/ionis-pharmaceuticals-inc-ions-receives-consensus-rating-of-hold-from-brokerages/1660400.html.
Ionis Pharmaceuticals (NASDAQ:IONS) traded up 0.07% on Tuesday, reaching $46.12. The company had a trading volume of 338,238 shares. The company’s 50 day moving average is $46.55 and its 200-day moving average is $38.87. Ionis Pharmaceuticals has a one year low of $19.59 and a one year high of $57.00. The firm’s market capitalization is $5.59 billion.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc, formerly Isis Pharmaceuticals, Inc, is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Company operates through two segments: Ionis Core and Akcea Therapeutics. The Company’s Ionis Core segment is developing a drug discovery platform.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/ionis-pharmaceuticals-inc-ions-receives-consensus-rating-of-hold-from-brokerages/1660400.html
Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.